Galderma Group

Galderma Group

GALD.SW
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

GALD.SW · Stock Price

CHF 167.50+67.75 (+67.92%)
Market Cap: $50.1B

Historical price data

Market Cap: $50.1BFounded: 1981Employees: 5000-10000HQ: Lausanne, Switzerland

Overview

Galderma's mission is to advance dermatology for every skin story, leveraging its position as the sole global, scaled pure-play in the field. Its key achievement is building an integrated, three-pillar business model—Therapeutic Dermatology, Injectable Aesthetics, and Dermatological Skincare—that drives growth across medical and consumer markets. The strategy centers on innovation through a proprietary R&D engine, global commercial execution, and capitalizing on its independence post-2019 Nestlé separation and successful 2024 IPO. This approach has established a leading portfolio with strong brand recognition and a robust pipeline.

DermatologyAesthetic Medicine

Technology Platform

Integrated platform combining advanced formulation & drug delivery science for topicals, proprietary biomaterial engineering for injectable aesthetics, and deep translational research in skin biology.

Funding History

2
Total raised:$4.8B
IPO$2.3B
Debt$2.5B

FDA Approved Drugs

20
NEMLUVIOBLAAug 12, 2024
EPSOLAYNDAApr 22, 2022
TWYNEONDAJul 26, 2021

Company Timeline

1981Founded

Founded in Lausanne, Switzerland

2019Debt

Debt: $2.5B

2021FDA Approval

FDA Approval: TWYNEO

2022FDA Approval

FDA Approval: EPSOLAY

2024IPO

IPO — $2.3B

2024FDA Approval

FDA Approval: NEMLUVIO